ORIC data suggest rinzimetostat may enhance prostate cancer sensitivity to androgen receptor inhibition

Bitget2026/10/23 07:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ORIC Pharmaceuticals presented preclinical and patient-sample findings at ESMO Congress 2026 supporting rinzimetostat’s potential to enhance prostate cancer sensitivity to androgen receptor inhibition.
Preclinical models showed rinzimetostat retained effectiveness against a mutation linked to mevrometostat resistance; no rinzimetostat-resistant cells emerged.
Samples from treated patients with metastatic castration-resistant prostate cancer showed biological changes consistent with increased dependence on androgen receptor signaling.
The findings support broader prostate cancer development, including the ongoing Himalayas-1 Phase 3 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230315PRIMZONEFULLFEED9851715) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ORIC data suggest rinzimetostat may enhance prostate cancer sensitivity to androgen receptor inhibition

You may also like

Crypto prices